CSF excitatory amino acids and severity of illness in Alzheimer's disease

J. G. Csernansky*, M. E. Bardgett, Y. I. Sheline, J. C. Morris, J. W. Olney

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

63 Scopus citations

Abstract

Researchers have proposed that increased release of excitatory amino acids (EAAs) is involved in the pathogenesis of dementia of the Alzheimer type (DAT), and CSF EAA concentrations have been measured to obtain evidence in support of this hypothesis. However, previous comparisons of CSF EAA concentrations in patients with DAT and in controls have yielded inconsistent results, perhaps because patient samples have been heterogeneous as to dementia severity. To determine whether there are changes in CSF concentrations of EAAs related to severity of illness in patients with DAT, we measured CSF concentrations of glutamate, aspartate, and taurine in 32 subjects with DAT, in whom we also assessed the severity of illness using clinical and neuropsychological measures, and 11 age-matched controls. The results suggested that increased CSF aspartate and glutamate concentrations, as well as decreased taurine concentrations, may occur in some persons with more advanced symptoms of DAT.

Original languageEnglish (US)
Pages (from-to)1715-1720
Number of pages6
JournalNeurology
Volume46
Issue number6
DOIs
StatePublished - Jun 1996

ASJC Scopus subject areas

  • Clinical Neurology

Fingerprint Dive into the research topics of 'CSF excitatory amino acids and severity of illness in Alzheimer's disease'. Together they form a unique fingerprint.

Cite this